At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLYM CLIMB BIO INC
Trading 07-15 11:50:47 EDT
13.58
+0.34
+2.57%
High13.73Low12.75Vol177.57K
Open13.14D1 Closing13.24Amplitude7.40%
Mkt Cap777.60MTradable Cap562.63MTotal Shares57.26M
T/O2.37MT/O Rate0.43%Tradable Shares41.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Climb Bio Director Breanna Maurine Celebi Files Initial Beneficial Ownership Statement
Reuters  ·  07-02
Climb Bio Director Breanna Maurine Celebi Files Initial Beneficial Ownership Statement
Climb Bio Names Breanna O’reilly to Board After Andrew Levin Resigns
Reuters  ·  07-02
Climb Bio Names Breanna O’reilly to Board After Andrew Levin Resigns
Climb Bio Price Target Maintained with a $20.00/share by HC Wainwright & Co.
Dow Jones  ·  06-24
Climb Bio Price Target Maintained with a $20.00/share by HC Wainwright & Co.
Tango Therapeutics appoints Robert Azelby to board of directors
Reuters  ·  06-23
Tango Therapeutics appoints Robert Azelby to board of directors
BRIEF-Climb Bio - Enters Open Market Sale Agreement With Jefferies - SEC Filing
Reuters  ·  06-13
BRIEF-Climb Bio - Enters Open Market Sale Agreement With Jefferies - SEC Filing
Climb Bio enters Jefferies ATM equity distribution agreement for up to $100 million stock sale
Reuters  ·  06-13
Climb Bio enters Jefferies ATM equity distribution agreement for up to $100 million stock sale
Climb Bio - Enters Open Market Sale Agreement With Jefferies Dated June 12, 2026 - SEC Filing
THOMSON REUTERS  ·  06-13
Climb Bio - Enters Open Market Sale Agreement With Jefferies Dated June 12, 2026 - SEC Filing
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)
TIPRANKS  ·  06-12
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)
Climb Bio price target raised to $20 from $19 at BTIG
TIPRANKS  ·  06-12
Climb Bio price target raised to $20 from $19 at BTIG
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)
TIPRANKS  ·  06-12
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)
Climb Bio Is Maintained at Buy by BTIG
Dow Jones  ·  06-11
Climb Bio Is Maintained at Buy by BTIG
Climb Bio reports initial Phase 1b data showing platelet responses for budoprutug in immune thrombocytopenia trial
Reuters  ·  06-11
Climb Bio reports initial Phase 1b data showing platelet responses for budoprutug in immune thrombocytopenia trial
Climb Bio - Announces Initial Phase 1B Data for Budoprutug in Immune Thrombocytopenia
THOMSON REUTERS  ·  06-11
Climb Bio - Announces Initial Phase 1B Data for Budoprutug in Immune Thrombocytopenia
Climb Bio - Enrollment Ongoing in 1000 Mg Cohort With Data Expected by Year-End 2026
THOMSON REUTERS  ·  06-11
Climb Bio - Enrollment Ongoing in 1000 Mg Cohort With Data Expected by Year-End 2026
Climb Bio sets 5,216,105-share cap under 2021 equity incentive plan
Reuters  ·  06-09
Climb Bio sets 5,216,105-share cap under 2021 equity incentive plan
Climb Bio initiated with a Buy at Guggenheim
TIPRANKS  ·  06-08
Climb Bio initiated with a Buy at Guggenheim
Guggenheim Initiates Climb Bio at Buy With $35 Price Target
MT Newswires Live  ·  06-08
Guggenheim Initiates Climb Bio at Buy With $35 Price Target
Climb Bio Price Target Maintained With a $19.00/Share by BTIG
Dow Jones  ·  06-08
Climb Bio Price Target Maintained With a $19.00/Share by BTIG
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)
TIPRANKS  ·  06-06
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)
BRIEF-Climb Bio - Announces Initial Phase 1 Safety Data For CLYM116 - SEC Filing
Reuters  ·  06-05
BRIEF-Climb Bio - Announces Initial Phase 1 Safety Data For CLYM116 - SEC Filing

Introduction

Company Name.
CLIMB BIO INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Issue price:
--